

01-12-03


Express Mail Label No. ED 283324435 US

Date of Deposit: January 10, 2006

TFW 7642

Attorney Docket No. CST-138 CIP 2

PAIR Customer No.: 31012



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Comb *et al.*

ASSIGNEE: Cell Signaling Technology, Inc.

SERIAL NUMBER: 10/014,485

EXAMINER: Canella, Karen A.

FILING DATE: November 11, 2001

ART UNIT: 1642

FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES
USING PEPTIDE LIBRARIES AS ANTIGENS

January 10, 2006

Danvers, Massachusetts

Mail Stop AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Attached hereto for filing in the above-identified patent application are the following:

- ☒ Transmittal Letter (w/duplicate) (2 pages);
- ☒ Supplemental Information Disclosure Statement (3 pages);
- ☒ IDS Form – PTO 1449 (w/duplicate) (2 pages);
- ☒ References AA, BA and CAE - CAH (6 references);
- ☒ Return Postcard.

Respectfully submitted,

James Gregory Cullem, Esq., Reg. No. 43,569

Intellectual Property Counsel

Andrew J. Warner, J.D., Reg. No. 56, 049

Patent Agent


CELL SIGNALING TECHNOLOGY, INC.

Express Mail Label No.: ED 283324435 US

Attorney Docket No.: CST-138 CIP 2

Date of Deposit: January 10, 2006

PAIR Customer No.: 31012



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Comb, *et al*
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.
SERIAL NUMBER: 10/014,485 EXAMINER: Canella, Karen A.
FILING DATE: November 11, 2001 ART UNIT: 1642
FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES
USING PEPTIDE LIBRARIES AS ANTIGENS

01/13/2006 HDEMESS1 00000012 501774 10014485

01 FC:1806 180.00 DA

January 10, 2006

Danvers, Massachusetts

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent or Application Documents:

Suiko, <i>et al</i>	United States	5,716,836
---------------------	---------------	-----------

Foreign Patent Documents:

Changnuad, <i>et al</i>	WO	98/29452
-------------------------	----	----------

Other Prior Art – Non Patent Literature Documents:

Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
Kolle, <i>et al.</i> , <i>FEBS</i> 421: 109-114 (1998)
Levine, <i>et al.</i> , <i>Journal of Immunological Methods</i> 124:239 (1989)
Hinson, <i>et al.</i> , <i>Adv. Exp. Med. Biol.</i> 387: 47-55 (1996)
Glenney, <i>et al.</i> , <i>Journal of Immunological Methods</i> , 109: 277-285 (1988)

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☐ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

This Information Disclosure Statement is being filed:

- ☒ after the mailing of a first Office Action on the merits, but before the mailing date of a final Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the application; and

- ☐ is accompanied by the following statement:

☐ Applicant(s) hereby state(s) that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement (37 C.F.R §1.97(e)(1)); or

☐ Applicant(s) hereby state(s) that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned representative signing this certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in Rule 1.56(c) more than three months prior to the filing of this information disclosure (37 C.F.R §1.97(e)(2)); and

- ☒ is accompanied by the fee set forth in 37 C.F.R. §1.17(p):


- ☐ a check for the required fee is enclosed herewith; or
- ☒ the Commissioner is hereby authorized to charge the required fee (and any other fees that may be due) to U.S. Deposit Account No. 50-1774, Ref. No. CST-138 CIP 2.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Reference No. CST-138 CIP 2.

Respectfully submitted,



James Gregory Cullem, Esq., Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.

Dated: January 10, 2006

 Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/014,485
	Filing Date	November 11, 2001
	First Named Inventor	Comb <i>et al.</i>
	Group Art Unit	1642
	Examiner Name	Canella, Karen A.
	Attorney Docket Number	CST-138 CIP 2

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AA	5,716,836	02/10/1998	Unitika Ltd.			11/14/1994

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication
	BA	WO	98/29452	Changnuad, et al	July 9, 1998

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CAE	Kolle, <i>et al.</i> , <i>FEBS</i> 421: 109-114 (1998)
	CAF	Levine, <i>et al.</i> , <i>Journal of Immunological Methods</i> 124: 239 (1989)
	CAG	Hinson, <i>et al.</i> , <i>Adv. Exp. Med. Biol.</i> 387: 47-55 (1996)
	CAH	Glenney, <i>et al.</i> , <i>Journal of Immunological Methods</i> 109: 277-285 (1988)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.